ArticleInternational journal of fertility & sterility2026
Pregnancy Outcome following Administration of Intravenous Immunoglobulin in Women with Unexplained Recurrent Implantation Failure: A Retrospective Cohort Study.
Article in International journal of fertility & sterility, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A substantial proportion of patients with recurrent implantation failure treated with partner lymphocyte immunotherapy achieved live birth within 3 years after immunization.Obstetrics & gynecology science · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Recurrent implantation failure (RIF) is a challenging condition affecting approximately 10% of in vitro fertilization (IVF) patients. Despite extensive investigations, up to half of cases remain unexplained. Immune dysregulation has been implicated in RIF, and intravenous immunoglobulin (IVIg) therapy has emerged as a potential treatment. However, the efficacy of IVIg for unexplained RIF remains controversial due to inconsistent study designs and outcomes. The aim of this study was to evaluate the impact of IVIg on pregnancy and live birth rates in women with unexplained RIF. Materials and Methods: A retrospective cohort study was conducted on 136 women with unexplained RIF undergoing frozen embryo transfer (FET) at Yazd Reproductive Sciences Research Institute and Reproductive Medicine Department of Madar Hospital, Yazd, Iran between April 2019 and March 2024. The study included women with unexplained RIF who underwent FET following endometrial preparation using hormonal therapy and received at least three doses of IVIg therapy. Baseline characteristics and pregnancy outcomes were compared. Results: A total of 68 patients were included in each group. The IVIg group had a significantly higher biochemical pregnancy rate compared to the control group [26(38.2%) vs. 13(19.1%), P=0.014]. Although clinical pregnancy, ongoing pregnancy, and live birth rates were numerically higher in the IVIg group, these differences did not reach statistical significance. Conclusion: Our findings suggest that IVIg treatment may be associated with higher biochemical pregnancy women with unexplained RIF. However, larger prospective studies are needed to confirm these results and to assess the longterm effects of IVIg on pregnancy outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.